Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response

Catherine Potter, Laura J. Gibbons, John D. Bowes, Heather J. Cordell, Kimme Hyrich, John D. Isaacs, Ann W. Morgan, Anthony G. Wilson, Anne Barton

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The introduction of tumour necrosis factor antagonists (anti-TNF) has greatly improved the treatment of rheumatoid arthritis, however, a significant proportion of patients fail to respond to therapy. We hypothesized that variants spanning the type 2 TNF receptor (TNFR2) and the TNF cleavage enzyme (TACE) genes contribute towards the observed variation in patient response (defined as the absolute change in 28-joint count disease activity score). Twenty-nine single nucleotide polymorphisms (SNPs) were genotyped in a large cohort of patients (n=602) and analysed by multivariate linear regression. Three SNPs (rs520916, rs652625, rs597519) mapping upstream of TNFR2 showed borderline evidence for association (P
    Original languageEnglish
    Pages (from-to)338-341
    Number of pages3
    JournalPharmacogenetics and Genomics
    Volume20
    Issue number5
    DOIs
    Publication statusPublished - May 2010

    Keywords

    • Antitumour necrosis factor therapy response
    • Pharmacogenetics
    • Polymorphism
    • Rheumatoid arthritis
    • TACE
    • TNFRSF1B

    Fingerprint

    Dive into the research topics of 'Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response'. Together they form a unique fingerprint.

    Cite this